For screening of tumors with a known low frequency of NTRK fusions where NGS is not routinely performed (e.g., colon cancer), Penault‐Llorca and colleagues recommend pan‐TRK immunohistochemistry (IHC) and, if positive, NGS.22 Here, TPM3 is linked to malignant colon neoplasm.